Takeda Net Invested Capital vs Common Stock Analysis
| TAK Stock | USD 13.19 0.11 0.84% |
Takeda Pharmaceutical financial indicator trend analysis is much more than just breaking down Takeda Pharmaceutical prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Takeda Pharmaceutical is a good investment. Please check the relationship between Takeda Pharmaceutical Net Invested Capital and its Common Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Net Invested Capital vs Common Stock
Net Invested Capital vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Takeda Pharmaceutical Net Invested Capital account and Common Stock. At this time, the significance of the direction appears to have totally related.
The correlation between Takeda Pharmaceutical's Net Invested Capital and Common Stock is 0.99. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Common Stock in the same time period over historical financial statements of Takeda Pharmaceutical Co, assuming nothing else is changed. The correlation between historical values of Takeda Pharmaceutical's Net Invested Capital and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Takeda Pharmaceutical Co are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Net Invested Capital i.e., Takeda Pharmaceutical's Net Invested Capital and Common Stock go up and down completely randomly.
Correlation Coefficient | 0.99 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Common Stock
Most indicators from Takeda Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. At this time, Takeda Pharmaceutical's Tax Provision is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.46 this year, although the value of Selling General Administrative will most likely fall to about 760.9 B.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 166.6B | 169.7B | 195.2B | 204.9B | Depreciation And Amortization | 591.5B | 718.7B | 826.5B | 867.8B |
Takeda Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
Takeda Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Takeda Pharmaceutical fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 12.8T | 12.9T | 13.2T | 14.0T | 16.1T | 16.9T | |
| Common Stock Shares Outstanding | 1.6B | 1.6B | 1.6B | 1.6B | 1.4B | 1.3B | |
| Short Long Term Debt Total | 5.1T | 4.6T | 4.3T | 4.4T | 5.0T | 5.3T | |
| Other Current Liab | 682.3B | 790.7B | 1.4T | 1.5T | 1.7T | 1.8T | |
| Total Current Liabilities | 2.2T | 1.8T | 2.1T | 2.5T | 2.9T | 3.0T | |
| Total Stockholder Equity | 4.7T | 5.2T | 5.7T | 6.4T | 7.3T | 7.7T | |
| Property Plant And Equipment Net | 1.4T | 1.5T | 1.6T | 1.7T | 1.9T | 2.0T | |
| Current Deferred Revenue | 200.5B | 119.5B | 588.0B | 616.5B | 709.0B | 744.4B | |
| Net Debt | 4.5T | 3.7T | 3.5T | 3.8T | 4.4T | 4.6T | |
| Retained Earnings | 1.4T | 1.5T | 1.5T | 1.5T | 1.4T | 1.4T | |
| Accounts Payable | 318.8B | 343.8B | 516.3B | 649.2B | 746.6B | 783.9B | |
| Cash | 637.6B | 966.2B | 849.7B | 533.5B | 480.2B | 597.2B | |
| Non Current Assets Total | 10.4T | 10.2T | 10.6T | 11.6T | 13.3T | 14.0T | |
| Non Currrent Assets Other | 103.8B | 100.3B | 82.6B | 63.3B | 72.8B | 69.2B | |
| Cash And Short Term Investments | 653.4B | 1.0T | 875B | 553.7B | 498.3B | 737.6B | |
| Net Receivables | 784.9B | 812.7B | 724.4B | 681.7B | 783.9B | 540.0B | |
| Common Stock Total Equity | 168.7B | 1.6T | 1.7T | 1.7T | 1.9T | 2.0T | |
| Short Term Investments | 15.8B | 36.6B | 25.3B | 20.2B | 18.2B | 17.2B | |
| Liabilities And Stockholders Equity | 12.8T | 12.9T | 13.2T | 14.0T | 16.1T | 16.9T | |
| Non Current Liabilities Total | 5.9T | 6.0T | 5.3T | 5.1T | 5.9T | 6.2T | |
| Inventory | 759.6B | 753.9B | 853.2B | 986.5B | 1.1T | 1.2T | |
| Other Current Assets | 114.2B | 122.8B | 141.1B | 160.9B | 185.0B | 194.2B | |
| Other Stockholder Equity | 1.6T | 1.6T | 1.6T | 1.6T | 1.9T | 2.0T | |
| Total Liab | 8.1T | 7.7T | 7.5T | 7.6T | 8.7T | 9.2T | |
| Property Plant And Equipment Gross | 1.4T | 1.5T | 2.5T | 2.7T | 3.1T | 3.3T | |
| Total Current Assets | 2.5T | 2.7T | 2.6T | 2.4T | 2.8T | 2.0T | |
| Accumulated Other Comprehensive Income | 92.6B | 366.1B | 934.2B | 1.5T | 1.7T | 1.8T | |
| Short Term Debt | 586.8B | 22.2B | 204.0B | 339.6B | 390.5B | 410.1B | |
| Common Stock | 1.7T | 1.7T | 1.7T | 1.7T | 1.9T | 2.0T | |
| Good Will | 4.0T | 4.0T | 4.4T | 4.8T | 5.5T | 5.8T | |
| Intangible Assets | 4.2T | 3.9T | 3.8T | 4.3T | 4.9T | 5.2T | |
| Other Assets | 10.4T | 454.1B | 678.7B | 429.3B | 493.7B | 469.0B | |
| Other Liab | 1.1T | 831.0B | 1.2T | 544.1B | 625.7B | 713.1B | |
| Net Tangible Assets | (3.8T) | (3.5T) | (2.8T) | (2.5T) | (2.3T) | (2.4T) | |
| Long Term Debt | 4.5T | 4.6T | 4.1T | 4.0T | 4.6T | 2.9T | |
| Long Term Investments | 369.5B | 348.4B | 330.1B | 378.9B | 435.7B | 286.4B | |
| Short Long Term Debt | 586.8B | 22.2B | 204.0B | 339.6B | 390.5B | 328.0B | |
| Treasury Stock | (74.4B) | (57.1B) | (87.5B) | (59.6B) | (53.6B) | (56.3B) | |
| Property Plant Equipment | 1.4T | 1.5T | 1.6T | 1.7T | 1.9T | 1.1T | |
| Long Term Debt Total | 4.5T | 4.6T | 4.1T | 4.0T | 4.6T | 3.3T |
Currently Active Assets on Macroaxis
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Takeda Stock analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.12) | Dividend Share 184 | Earnings Share 0.36 | Revenue Per Share 1.3 K | Quarterly Revenue Growth 0.013 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.